Parkside Financial Bank & Trust’s Cytek Biosciences CTKB Stock Holding History

Parkside Financial Bank & Trust’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$289	Sell	66 -127	-66%	-$600	﹤0.01%	2620
2025 Q4	$976	Buy	193 +127	+192%	+$590	﹤0.01%	2355
2025 Q3	$230	Hold	66	–	–	﹤0.01%	2649
2025 Q2	$225	Buy	+66	New	+$220	﹤0.01%	2663
2025 Q1	–	Sell	-39	Closed	-$254	–	2741
2024 Q4	$254	Sell	39 -21	-35%	-$125	﹤0.01%	2015
2024 Q3	$333	Buy	60 +39	+186%	+$221	﹤0.01%	1906
2024 Q2	$118	Buy	21 +5	+31%	+$30	﹤0.01%	2011
2024 Q1	$108	Hold	16	–	–	﹤0.01%	2010
2023 Q4	$146	Sell	16 -751	-98%	-$4.73K	﹤0.01%	1996
2023 Q3	$4.23K	Buy	767 +382	+99%	+$3.06K	﹤0.01%	1427
2023 Q2	$3.29K	Buy	+385	New	+$3.45K	﹤0.01%	1520

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Parkside Financial Bank & Trust's CTKB Position: Q1 2026 in Review

Parkside Financial Bank & Trust reduced its Cytek Biosciences (CTKB) stake by 66% in Q1 2026, selling an estimated $600 and leaving 66 shares worth $289. The position accounts for ﹤0.01% of the portfolio, ranked #2620.

Parkside Financial Bank & Trust first reported a position in CTKB in Q2 2023 and has held it in 11 quarters since. The position peaked at $4.23K in Q3 2023. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

Parkside Financial Bank & Trust held 66 shares of Cytek Biosciences worth $289 as of Q1 2026.
Parkside Financial Bank & Trust sold 127 Cytek Biosciences shares in Q1 2026, an estimated $600.
Cytek Biosciences made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #2620 holding.
Parkside Financial Bank & Trust first reported a position in Cytek Biosciences in Q2 2023 and has held it in 11 quarters since.
Parkside Financial Bank & Trust's Cytek Biosciences position peaked at $4.23K in Q3 2023.
165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.